These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2687813)

  • 41. National Academy of Neuropsychology/Division 40 of the American Psychological Association Practice Survey of Clinical Neuropsychology in the United States. Part II: Reimbursement experiences, practice economics, billing practices, and incomes.
    Sweet JJ; Peck EA; Abramowitz C; Etzweiler S
    Arch Clin Neuropsychol; 2003 Aug; 18(6):557-82. PubMed ID: 14591431
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overview of biotherapy and nursing considerations.
    Coleman C
    J Intraven Nurs; 1998; 21(6):367-73. PubMed ID: 10392103
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NIH common fund concerns some in cancer research community.
    Vanchieri C
    J Natl Cancer Inst; 2007 Mar; 99(5):345. PubMed ID: 17341723
    [No Abstract]   [Full Text] [Related]  

  • 44. Stat bite: State mandates for insurance coverage of clinical trials.
    J Natl Cancer Inst; 2003 Sep; 95(17):1269. PubMed ID: 12953077
    [No Abstract]   [Full Text] [Related]  

  • 45. [Conducting a cost-effectiveness trial in oncology: justification and method].
    Lejeune C; Binquet C; Bonnetain F
    Bull Cancer; 2009 May; 96(5):603-7. PubMed ID: 19435689
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effects of managed care and competition on community-based clinical research.
    Carpenter WR; Weiner BJ; Kaluzny AD; Domino ME; Lee SY
    Med Care; 2006 Jul; 44(7):671-9. PubMed ID: 16799362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reimbursement of biotherapy: present status, future directions--perspectives of the third-party payer.
    Gleeson S
    Semin Oncol Nurs; 1992 Nov; 8(4 Suppl 1):13-6. PubMed ID: 1462053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A conversation with Lee N. Newcomer, MD, MHA. Payments with purpose. Interview by John Marcille.
    Newcomer LN
    Manag Care; 2011 Dec; 20(12):36-40. PubMed ID: 22259875
    [No Abstract]   [Full Text] [Related]  

  • 49. Cancer and diabetes: are there similarities?
    Oldham RK
    Mol Biother; 1990 Sep; 2(3):130-1. PubMed ID: 2222895
    [No Abstract]   [Full Text] [Related]  

  • 50. Bundled payment: practice savior or killer?
    Ullamn K
    Am J Manag Care; 2013; 19 Spec No. 3():E2. PubMed ID: 23725325
    [No Abstract]   [Full Text] [Related]  

  • 51. Successful clinical trials in the private sector: the National Biotherapy Study Group (NBSG) experience.
    Avent R; Birch R; Oldham RK; Arnold J
    Prog Clin Biol Res; 1990; 339():419-23. PubMed ID: 2392434
    [No Abstract]   [Full Text] [Related]  

  • 52. Paying for cancer care under the diagnosis-related group reimbursement.
    JAMA; 1985 Aug 23-30; 254(8):1032. PubMed ID: 3927015
    [No Abstract]   [Full Text] [Related]  

  • 53. The biotherapy of cancer--III. Proceedings of a symposium; May 19, 1989; San Francisco, California.
    Oncol Nurs Forum; 1989; 16(6 Suppl):3-47. PubMed ID: 2594552
    [No Abstract]   [Full Text] [Related]  

  • 54. WellPoint initiative may challenge some practices.
    Caffrey MK
    Am J Manag Care; 2014 Aug; 20(11 Spec No.):E3. PubMed ID: 25764583
    [No Abstract]   [Full Text] [Related]  

  • 55. Radiation Oncology Clinical Trial Design: An Opportunity to Evaluate Value.
    Shah C; Ward M; Singer ME
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):674-675. PubMed ID: 31540597
    [No Abstract]   [Full Text] [Related]  

  • 56. An oncologist's perspective: preparation for new payment models in cancer care.
    Apte SM
    Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP169-SP172. PubMed ID: 28665674
    [No Abstract]   [Full Text] [Related]  

  • 57. Three questions about costs and cancer clinical trials.
    Chirikos TN
    Cancer Control; 2003; 10(1):71-8. PubMed ID: 12598857
    [No Abstract]   [Full Text] [Related]  

  • 58. Method II reimbursement continues to raise questions for providers, patients.
    Riley JB; Pristave RJ
    Nephrol News Issues; 1990 Feb; 4(2):19-20. PubMed ID: 2320132
    [No Abstract]   [Full Text] [Related]  

  • 59. Reimbursement for patients enrolled in clinical trials.
    Kennedy BJ
    Cancer Invest; 1994; 12(4):444-6. PubMed ID: 8032968
    [No Abstract]   [Full Text] [Related]  

  • 60. Future projections in biotherapy.
    Rieger PT
    Semin Oncol Nurs; 1996 May; 12(2):163-71. PubMed ID: 8727803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.